Nanomedicine. 2018 May 9. pii: S1549-9634(18)30089-3. doi: 10.1016/j.nano.2018.04.017. [Epub ahead of print]

Nanofiber technology in the ex vivo expansion of cord blood-derived hematopoietic stem cells.

Ferreira MSV¹, Mousavi SH².

Abstract

Umbilical cord blood (CB) can be used as an alternative source of hematopoietic stem cells (HSCs) for transplantation in hematological and non- hematological disorders. Despite several recognized advantages the limited cell number in CB one unit still restricts its clinical use. The success of transplantation is greatly depending on the levels of total nucleated cell and CD34+ cell counts. Thus, many ex vivo strategies have been developed within the last decade in order to solve this obstacle, with more or less success, mainly determined by the degree of difficulty related with maintaining HSCs self-renewal and stemness properties after long-term expansion. Different research groups have developed very promising and diverse CB-derived HSC expansion strategies using nanofiber scaffolds. Here we review the state-of-the-art of nanofiber technology-based CB-derived HSC expansion.